Blog

Emma M. Groarke: We found that there was more than 40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS

Photo from Emma M. Groarke/X

Feb 8, 2024, 14:58

Emma M. Groarke: We found that there was more than 40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS

Emma M. Groarke, Hematologist at the National Institutes of Health (NIH), shared a post on X/Twitter:

“Very excited to share our NIH-Mayo Clinic collaboration just published in Blood Journal focused on the thrombotic manifestations occurring in VEXAS.

We found that there was >40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS; many events occurred at initial disease presentation. Cardiac or pulmonary involvement appear to confer increased risk.

Thrombosis seems to be driven by inflammation. Patients almost ubiquitously had high FVIII levels and many had high VWD antigen and activity.”

Source: Emma M. Groarke/X

Blood Journal cancer Emma M. Groarke Mayo Clinic National Institutes of Health (NIH). NIH OncoDaily Oncology venous and arterial thrombosis Vexas VWD antigen

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage